Patents by Inventor Andre Johannes Niestroj
Andre Johannes Niestroj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150038516Abstract: Compounds of general Formula I: wherein R1, R2, R3, x, A and Ra are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.Type: ApplicationFiled: May 5, 2014Publication date: February 5, 2015Applicant: AstraZeneca ABInventors: Hans Allgeier, Martin Augustin, SR., Anke Muller, Lutz Zeitlmann, Andreas Marquardt, Michael A. Pleiss, Ulrich Heiser, Andre Johannes Niestroj
-
Patent number: 8716296Abstract: Compounds of general formula (I): are useful as inhibitors of cyclin dependent kinases such as CDK9.Type: GrantFiled: October 13, 2008Date of Patent: May 6, 2014Assignee: Ingenium Pharmaceuticals GmbHInventors: Hans Allgeier, Martin Augustin, Anke Müller, Lutz Zeitlmann, Andreas Marquardt, Michael A. Pleiss, Ulrich Heiser, André Johannes Niestroj
-
Patent number: 8685664Abstract: Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.Type: GrantFiled: April 11, 2008Date of Patent: April 1, 2014Assignee: Probiodrug AGInventors: Hans-Ulrich Demuth, Torsten Hoffmann, Andre Johannes Niestroj, Stephan Schilling, Ulrich Heiser
-
Patent number: 8470781Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.Type: GrantFiled: July 29, 2008Date of Patent: June 25, 2013Assignee: Probiodrug AGInventors: Stephan Schilling, Torsten Hoffmann, Andre Johannes Niestroj, Hans-Ulrich Demuth, Ulrich Heiser
-
Publication number: 20100249149Abstract: are useful as inhibitors of cyclin dependent kinases such as CDK9.Type: ApplicationFiled: October 13, 2008Publication date: September 30, 2010Inventors: Hans Allgeier, Martin Augustin, Anke Müller, Luz Zeitlmann, Andreas Marquardt, Michael A. Pleiss, Ulrich Heiser, André Johannes Niestroj
-
Publication number: 20100159032Abstract: The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, LiCl, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof.Type: ApplicationFiled: December 3, 2009Publication date: June 24, 2010Applicant: PROBIODRUG AGInventors: Ingo Schulz, Stephan Schilling, Hans-Ulrich Demuth, Ulrich Heiser, Andre Johannes Niestroj, Steffen Rossner
-
Patent number: 7655684Abstract: Compounds that act as inhibitors of QC including those represented by the general formulae 1 to 9: and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Corea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.Type: GrantFiled: March 12, 2008Date of Patent: February 2, 2010Assignee: Probiodrug AGInventors: Stephan Schilling, Andre Johannes Niestroj, Ulrich Heiser, Hans-Ulrich Demuth, Mirko Buchholz
-
Patent number: 7608577Abstract: The present invention relates to compounds of the general formula 1 and pharmaceutically acceptable salts thereof, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus in mammals.Type: GrantFiled: August 9, 2002Date of Patent: October 27, 2009Assignee: OSI Pharmaceuticals, Inc.Inventors: Ulrich Heiser, André Johannes Niestroj, Torsten Hoffmann, Hans-Ulrich Demuth
-
Patent number: 7592467Abstract: The present invention relates to novel inhibitors of prolyl endopeptidase of formula (1) wherein I, A, X, Y and Z are specified in the description. The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.Type: GrantFiled: April 7, 2006Date of Patent: September 22, 2009Assignee: Probiodrug AGInventors: Andre Johannes Niestroj, Ulrich Heiser, Hans-Ulrich Demuth, Susanne Aust
-
Publication number: 20090149394Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.Type: ApplicationFiled: July 29, 2008Publication date: June 11, 2009Applicant: PROBIODRUG AGInventors: Stephan Schilling, Torsten Hoffmann, Andre Johannes Niestroj, Hans-Ulrich Demuth, Ulrich Heiser
-
Patent number: 7462599Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.Type: GrantFiled: October 15, 2004Date of Patent: December 9, 2008Assignee: Probiodrug AGInventors: Stephan Schilling, Torsten Hoffmann, André Johannes Niestroj, Hans-Ulrich Demuth, Ulrich Heiser
-
Publication number: 20080286810Abstract: Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.Type: ApplicationFiled: April 11, 2008Publication date: November 20, 2008Applicant: PROBIODRUG AGInventors: Hans-Ulrich Demuth, Torsten Hoffmann, Andre Johannes Niestroj, Stephan Schilling, Ulrich Heiser
-
Patent number: 7304086Abstract: The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.Type: GrantFiled: February 4, 2005Date of Patent: December 4, 2007Assignee: Probiodrug AGInventors: Stephan Schilling, Mirko Buchholz, Andre Johannes Niestroj, Ulrich Heiser, Hans-Ulrich Demuth